Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

How BioVaxys' DPX platform creates anti-cancer immune response

Research Research, The Market Online
0 Comments| October 8, 2024

{{labelSign}}  Favorites
{{errorMessage}}

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustaining immune responses. Learn how BioVaxys is leveraging this groundbreaking platform to potentially revolutionize vaccines and treatments.

To keep up with the latest developments from the company, visit https://www.biovaxys.com/

This is third-party content provided by BioVaxys Technology Corp. (CSE:BIOV). Please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this company on the BioVaxys Technology Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

(Top photo: Adobe Stock)




{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company